When the government steps in between patients and their doctor to decide the value or price of a treatment, patient access suffers. That’s exactly what is predicted to happen to Part D medicines affected by the Inflation Reduction Act’s (IRA’s) flawed new price-setting program – both those directly price-set and also other therapeutic competitors within the same class.